Here, the inventors describe methods and compositions for targeting a TLR agonist to the tumor cell or stroma. Aspects of the disclosure relate to a polypeptide comprising a tumor targeting agent operatively linked to p(Man-TLR). Also disclosed are compositions and methods for treating cancer in a subject comprising administration of the polypeptide comprising the tumor targeting agent linked to p(Man-TLR) to the subject.

The invention relates to the diagnosis and treatment of diseases, including cancer and inflammatory disorders. The invention provides, and involves the use of, antibodies that bind collagen.

Anti-TF antibody drug conjugate and pharmaceutical compositions comprising the antibody drug-conjugate for use in the treatment of a solid cancer comprising administering to a subject a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an anti-TF antibody drug conjugate once a week for three consecutive weeks followed by a one week resting period without any administration of anti-TF ADC so that each cycle time is 28 days including the resting period.

The invention provides methods for selective targeting of live cells, which have undergone or are undergoing radiation or chemotherapy, at a site of interest with a cell-penetrating polypeptide. In one embodiment of the invention, the method comprises contacting the live cells with a cell-penetrating polypeptide comprising cell-penetrating determinants so that the cell-penetrating polypeptide binds extracellular DNA near or around the live cells so as to form a complex or association therewith such that the complex or associated polypeptide-DNA so bound bind the live cells and penetrates the live cells thereby selectively targeting live cells at a site of interest with a cell-penetrating polypeptide.

Disclosed herein are chemotherapeutic methods for the treatment of cancer in humans. In at least one specific embodiment, the method can include administering a therapeutic effective amount of one or more p38 inhibitor compound or salt thereof to a human. The method can also include administering a therapeutic effective of one or more IL-6 inhibitor or one or more IL-6 receptor inhibitor or salt thereof to the human. The method can also include administering a therapeutic effective amount of one or more cytotoxic compound or salt thereof to the human.

The present disclosure provides various core constructs. According to embodiments of the present disclosure, the core construct can be used to configure pharmaceutical molecules. In particular, the core construct may be conjugated with a functional element via the click chemistry.

Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.

Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.

The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.

Present invention relates to a human lung tissues-active targeting immune nanoliposome of methylprednisolone, wherein, nanoliposomes loaded with therapy drugs is covalently coupled with nanobodies against human pulmonary surfactant protein A. Wherein, the therapy drug is methylprednisolone sodium succinate, the nanoliposome consists of phospholipids, cholesterols and long cycling materials. The molar ratio of the methylprednisolone sodium succinate to phospholipids within the nanoliposome is 0.30-0.45. Present invention successfully provides a new human lung tissues targeting hormone preparation, wherein, the nanoliposome serves as a carrier, the nanobody against human pulmonary surfactant protein A serves as a specific lung tissue targeting ligand, methylprednisolone sodium succinate serves as a therapy drug. In accordance with present invention, an efficient, stable human lung tissues-active targeting immune nanoliposome, with specific active lung targeting, is prepared.